Ravelcare Limited shareholders unanimously approved all four resolutions passed at the company's 8th Annual General Meeting held on September 23, 2026. The detailed voting results submitted to BSE confirm that every agenda item received 100% of the valid votes cast in its favour.

The meeting, conducted through Video Conferencing and Other Audio-Visual Means, was chaired by Chairman and Managing Director Ayush Mahesh Varma. The Company Secretary confirmed that the annual report and notice were delivered in compliance with statutory requirements, and the auditor's report was taken as read without any qualifications from statutory or secretarial auditors.

Key resolutions passed

Shareholders approved several key governance matters during the session:

• Adoption of Financial Statements: The audited financial statements for FY26, along with the Board of Directors' report and Auditors' reports, were received and adopted.
• Director Reappointment: Mrs. Anita Mahesh Varma was reappointed as a director retiring by rotation.
• Managing Director Reappointment: A special resolution was passed to reappoint Ayush Varma as Managing Director.
• Whole-time Director Reappointment: A special resolution was passed to reappoint Maheshkumar Varma as Whole-time Director.

Voting process and scrutiny

E-voting facilities were provided under Section 108 of the Companies Act, 2013. The voting window opened at 9:00 am on September 20, 2026, and closed at 5:00 pm on September 22, 2026. Additionally, voting facilities remained available during the meeting for members who had not cast their votes earlier. CS Vishal Thawani of M/s. VTSN and Associates LLP served as the scrutinizer to ensure fair and transparent conduct of the e-voting process.

Detailed voting results

The scrutinizer’s report confirms that a total of 50,05,999 votes were polled across all resolutions. Promoters and promoter group members cast 50,01,997 votes, while public non-institutional shareholders cast 4,002 votes. Institutional shareholders did not participate in the voting. No votes were cast against any resolution, and there were no abstentions or invalid votes.

What the Numbers Show

The voting data highlights a significant concentration of voting power among promoters. Promoters accounted for 99.92% of the total votes polled (50,01,997 out of 50,05,999), while public non-institutional shareholders contributed only 0.08% (4,002 votes). This structure ensured that all resolutions passed with absolute unanimity among participating shareholders, reflecting strong promoter alignment with the board's proposals.

Ravelcare has scheduled its 8th Annual General Meeting (AGM) for Wednesday, September 23, 2026, at 11:30 am via Video Conferencing. The meeting agenda includes the reappointment of key directors and the adoption of audited financial statements for FY26.

Corporate Governance Updates

Shareholders will vote on the reappointment of Mr. Ayush Varma as Managing Director for a further period of three years, effective June 20, 2027. His remuneration is capped at ₹75 lakhs per annum. The Board also seeks approval for the reappointment of Mr. Maheshkumar Varma as Whole-time Director for three years, with remuneration up to ₹30 lakhs per annum.

Additionally, Mrs. Anita Mahesh Varma retires by rotation and offers herself for reappointment as Non-Executive Director. The cut-off date for determining shareholder eligibility for voting is September 16, 2026. Remote e-voting will commence on September 20, 2026, at 9:00 am and end on September 22, 2026, at 5:00 pm.

FY26 Financial Performance

For the fiscal year ended March 31, 2026, Ravelcare reported revenue from operations of ₹2,695.43 lakhs, a 7.9% increase over the previous year. Profit after tax stood at ₹515.40 lakhs, representing a net profit margin of 19.1%. The company remains debt-free with a net worth of ₹3,740.84 lakhs.

Other income declined to ₹8.29 lakhs from ₹31.91 lakhs in the prior year. Total expenses rose to ₹1,996.47 lakhs from ₹1,826.44 lakhs. The Board did not propose any dividend for FY26, opting to preserve resources for growth initiatives.

Product Expansion and Strategy

The company launched Ravel PRO, a clinical haircare line, in June 2026. This range targets specific concerns such as hair fall and dandruff and is available across major e-commerce and quick-commerce platforms. Two additional PRO products are scheduled for launch in September 2026.

Management plans to launch an AI-led diagnostic skincare range in the second half of FY27. Funds from the December 2025 IPO, which raised ₹2,410.20 lakhs, remain largely unutilised and are held in bank fixed deposits. These funds are earmarked for backward integration into manufacturing and general corporate purposes.